摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,6-difluoro-2-(trichloromethyl)-1H-benzimidazole | 673487-28-0

中文名称
——
中文别名
——
英文名称
5,6-difluoro-2-(trichloromethyl)-1H-benzimidazole
英文别名
5,6-difluoro-2-trichloromethyl-1H-benzoimidazole
5,6-difluoro-2-(trichloromethyl)-1H-benzimidazole化学式
CAS
673487-28-0
化学式
C8H3Cl3F2N2
mdl
——
分子量
271.481
InChiKey
GNKRJZXKNZQBJQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    356.5±42.0 °C(Predicted)
  • 密度:
    1.753±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Octahydropyrrolo[3,4-C]pyrrole derivatives
    摘要:
    本发明涉及式(I)的八氢吡咯并[3,4-c]吡咯衍生物,以及其制备方法、含有该衍生物的组合物和用途。
    公开号:
    US20060111416A1
  • 作为产物:
    参考文献:
    名称:
    Synthesis of novel histamine H4 receptor antagonists
    摘要:
    This letter describes the discovery and synthesis of a series of octahydropyrrolo[3,4-c]pyrrole based selective histamine hH4 receptor antagonists. The amidine compound 20 was found to be a potent and selective histamine H4 receptor antagonist with moderate clearance and a high volume of distribution. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.11.098
点击查看最新优质反应信息

文献信息

  • Heterocyclic compound and use thereof
    申请人:Takanobu Kuroita
    公开号:US20100137587A1
    公开(公告)日:2010-06-03
    Compounds represented by the formulas wherein each symbol is as defined in the specification, and a prodrug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.
    由以下公式表示的化合物,其中每个符号如规范中定义,并且其前药具有优越的肾素抑制活性,可用作预防或治疗高血压、高血压引起的各种器官损伤等药物。
  • Heterocyclic compounds
    申请人:——
    公开号:US20040058934A1
    公开(公告)日:2004-03-25
    Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H 4 receptor, including allergic rhinitis.
    某些噻吩吡咯基和呋喃吡咯基化合物被揭示为治疗或预防由组胺H4受体介导的疾病和病症,包括过敏性鼻炎的有用药物。
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    申请人:Kuroita Takanobu
    公开号:US20110178057A1
    公开(公告)日:2011-07-21
    Compounds represented by the formulas (I) (II) wherein each symbol is as defined in the specification, and a pro-drug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.
    由公式(I)(II)所代表的化合物,其中每个符号如规范中所定义,并且其前药具有优越的肾素抑制活性,并且可用作预防或治疗高血压、由高血压引起的各种器官损伤等的药物。
  • Octahydropyrrolo[3,4-c]pyrrole derivatives
    申请人:Pfizer Limited
    公开号:EP1671972A1
    公开(公告)日:2006-06-21
    The present invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives of formula (I): and to processes for the preparation thereof, compositions containing the same and the uses thereof.
    本发明涉及式(I)的八氢吡咯并[3,4-c]吡咯生物: 及其制备工艺、含有这些衍生物的组合物及其用途。
  • [EN] HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2004022060A2
    公开(公告)日:2004-03-18
    (1H-Benzoimidazol-2-YL)-(Piperazinyl)-Methanone derivatives of formula (I) and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders (I) wherein B and B1 are C or up to one of B and B1 may be N; Y is O, S or NR2, where R2 is H or C1-4alkyl; Z is O or S; R8 is H and R9 is (a), where R10 Is H or C1-4alkyl, or R8 and R9 are taken together with their N of attachment to form (b); n is 1 or 2; m is 1 or 2; n + m is 2 or 3; other substituents as defined in claim 1.
    (1H-苯并咪唑-2-基)-(哌嗪基)-甲酰胺类化合物(I)及其相关化合物,作为组胺H4受体拮抗剂用于治疗炎症性和过敏性疾病。 其中,B和B₁是C,或者B和B₁中至多一个为N;Y是O、S或NR₂,其中R₂是H或C₁₋₄烷基;Z是O或S;R₈是H,且R₉是(a),其中R₁₀是H或C₁₋₄烷基,或者R₈和R₉与它们的连接N原子一起形成(b);n是1或2;m是1或2;n + m是2或3;其他取代基如权利要求1所述。
查看更多